Motif Bio PLC’s (LON:MTFB) “Buy” Rating Reaffirmed at Northland Securities
Motif Bio PLC (LON:MTFB)‘s stock had its “buy” rating reaffirmed by research analysts at Northland Securities in a note issued to investors on Thursday, July 6th.
Other equities research analysts have also recently issued research reports about the company. Beaufort Securities reaffirmed a “speculative buy” rating and set a GBX 110 ($1.44) target price on shares of Motif Bio PLC in a research report on Wednesday, May 3rd. FinnCap reaffirmed a “buy” rating and set a GBX 125 ($1.63) target price on shares of Motif Bio PLC in a research report on Tuesday, May 30th.
Shares of Motif Bio PLC (MTFB) traded up 2.20% during mid-day trading on Thursday, reaching GBX 29.00. 217,632 shares of the company were exchanged. Motif Bio PLC has a 12 month low of GBX 21.44 and a 12 month high of GBX 68.25. The company’s 50-day moving average is GBX 30.59 and its 200 day moving average is GBX 28.78. The firm’s market capitalization is GBX 56.81 million.
WARNING: “Motif Bio PLC’s (LON:MTFB) “Buy” Rating Reaffirmed at Northland Securities” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/07/21/northland-securities-reaffirms-buy-rating-for-motif-bio-plc-lonmtfb-updated.html.
Motif Bio PLC Company Profile
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).
Receive News & Stock Ratings for Motif Bio PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio PLC and related stocks with our FREE daily email newsletter.